ASH annual meeting | New Orleans, LA, USAMore info A Phase I Trial Of Anti-KIR Monoclonal Antibody IPH2101 and Lenalidomide For Multiple Myeloma 527.81 KB Repeated Dosing Of Anti-KIR (IPH2101) As Maintenance Therapy In Ederly Patients With Acute Myeloid Leukemia 279.68 KB Anti-KIR Antibody Enhancement Of Anti-Lymphoma Activity Of Natural Killer Cells As Monotherapy and In Combination With Anti-CD20 401.35 KB Date Sat, 12/07/2013 - 09:20
